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CBFs inhibit cap-dependent translation. (A) Chemical structure of 
FA and silvestrol. (B) FA and silvestrol inhibit cap-dependent trans-
lation. Top: Schematic representation of the FF/HCV/Ren mRNA. 
Bottom: Dose-dependent inhibition of cap-dependent protein synthe-
sis by FA and silvestrol in Krebs-2 translation extracts programmed 
with FF/HCV/Ren mRNA (10 μg/ml). Luciferase activity (RLU) results 
are expressed relative to values obtained in the presence of vehicle 
(MeOH) control. Results are expressed as mean ± SEM of 2 experi-
ments. (C) A representative autoradiograph from in vitro translations 
performed in Krebs-2 extracts with [35S]methionine and programmed 
with FF/HCV/Ren mRNA. The position of migration of FF and Ren 
proteins is indicated on the right.
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CBFs inhibit translation initiation and stimulate eIF4A RNA-binding 
activity. (A) CBFs prevent 80S complex formation. [32P]-labeled CAT 
mRNA (200,000 cpm) was incubated with cycloheximide (CHX) in 
the presence of FA or vehicle (MeOH) in rabbit reticulocyte lysates. 
Reactions were resolved by centrifugation through glycerol gradients. 
Following centrifugation, fractions were collected and the amount of 
radioactivity determined by liquid scintillation counting. The total counts 
recovered from each gradient and the percentages of mRNA bound in 
80S complexes were: CAT mRNA/CHX + MeOH: 35,178 cpm, 19% 
binding; and CAT mRNA/CHX + FA: 37,655 cpm, 2% binding. (B) CBFs 
stimulate cross-linking of eIF4A to mRNA. Initiation factor preparations 
were cross-linked to [32P]-cap-labeled mRNA in the absence (lane 2) 
or presence of ATP (lanes 1 and 3–6), 0.6 mM m7GDP (lane 3), 0.6 
mM GDP (lane 4), MeOH (lane 5), or 50 μM FA (lane 6). Following 
nuclease digestion, samples were resolved by SDS-PAGE, and the gel 
was subjected to autoradiography. The position of migration of eIF4E, 
eIF4A, and eIF4B is indicated and is based on their known behavior in 
this assay (30). (C) CBFs stimulate the RNA-binding activity of eIF4AIf. 
[32P]-cap-labeled mRNA was cross-linked to recombinant eIF4AIf in 
the presence of MeOH (lane 1), 50 μM FA (lane 3), or 50 μM silves-
trol (lane 2). Following nuclease digestion, samples were resolved by 
SDS-PAGE, and the gel was subjected to autoradiography. (D) CBFs 
stimulate the RNA-binding activity of eIF4Ac. [32P]-cap-labeled mRNA 
was cross-linked to eIF4F in the presence of MeOH (lane 1) or 50 μM 
FA (lane 2). Following nuclease digestion, samples were resolved by 
SDS-PAGE, and the gel was subjected to autoradiography. Cross-
linking of a higher-molecular-mass species (>175 kDa) is indicated by 
“eIF4G ?” since it may reflect RNA-bound eIF4G.
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CBFs  have  been  previously 
shown to be capable of induc-
ing  apoptosis  (24).  To  assess 
the dose required for this event 
versus that required for trans-
lation  inhibition,  Jurkat  cells 
were  exposed  to  various  con-















CBFs cause RNA-dependent 
sequestration of eIF4A in vivo. 
Given  the  ability  of  silvestrol 
to stimulate the RNA-binding 













Effects of CBFs on protein, RNA, and DNA synthesis in vivo. (A) Dose-dependent inhibition of protein 
synthesis in vivo by CBFs. HeLa cells were incubated with the indicated concentrations of FA and sil-
vestrol for 1 hour, with [35S]methionine added 10 minutes before the end of the incubation. The rate of 
[35S]methionine (35S]-Met) incorporation is expressed relative to that of cells treated with vehicle (MeOH). 
Results are expressed as mean ± SEM of 2 experiments. (B) CBFs primarily impact protein synthesis in 
vivo. HeLa cells were incubated with 5 μM FA, 0.4 μM silvestrol, or vehicle (MeOH) for 1 hour. The rate 
of incorporation of each radioisotope tracer into TCA-insoluble material is expressed relative to that in 
MeOH-treated cells. Results are expressed as mean ± SEM of 2 experiments. (C) Inhibition of translation 
by CBFs is reversible. HeLa cells were incubated for 1 hour with 10 μM anisomycin, 5 μM FA, 0.4 μM 
silvestrol, or MeOH. Cells were then washed with PBS and incubated with medium lacking compound for 
the indicated times. Ten minutes before harvesting, [35S]methionine was added to the culture. The rate of 
[35S]methionine incorporation into TCA-insoluble material is expressed relative to that in MeOH-treated 
cells. Results are expressed as mean ± SEM of 3 experiments. Anisomycin acts a positive control, since 
recovery of protein synthesis from inhibition with this compound occurs within an hour of its removal 
from cells (65). (D) CBFs inhibit cap-dependent translation in vivo. Top: Schematic representation of 
pcDNA/Ren/HCV/FF expression vector. Bottom: Effect of FA on cap-dependent and HCV IRES–medi-
ated translation in 293 cells transfected with pcDNA/Ren/HCV/FF. Luciferase activity is expressed rela-
tive to that in MeOH-treated cells and is the mean ± SEM of 2 experiments. (E) Silvestrol does not 
induce eIF2α phosphorylation. HeLa cells were incubated for 2 hours in the presence of vehicle (DMSO), 
thapsigargin (2 μg/ml), or silvestrol (400 nM), after which extracts were analyzed by Western blotting. 
(F) Silvestrol induces apoptosis at concentrations higher than those required to inhibit protein synthesis. 
Jurkat cells were incubated with the indicated silvestrol concentrations for 13 hours, after which the rate 
of [35S]methionine incorporation or the percentage of living cells was measured. Results are expressed 
as mean ± SEM of 2 experiments.
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Silvestrol reverses chemoresistance mediated by PTEN inactivation or 





















































Silvestrol induces eIF4A association into RNAse-
sensitive heavy sedimenting complexes in vivo. 
(A) Effect of silvestrol on Jurkat cell polyribosomes. 
Jurkat cells were exposed to vehicle (MeOH) or 
0.2 μM silvestrol for 60 minutes. Cell extracts were 
prepared and treated with micrococcal nuclease 
(MN) where indicated. Reactions were resolved on 
10%–50% sucrose gradients by centrifugation in 
an SW40 rotor at 150,000 g for 2 hours. Fractions 
were collected from the gradients and monitored 
with an ISCO UA-6 UV detector. (B) Western blots 
demonstrating the position of migration of eIF4A, 
eIF4E, and eIF4G1 in sucrose fractions collected 
from untreated or MN-treated lysates prepared from 
cells exposed to MeOH or 0.2 μM silvestrol.
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Silvestrol alters chemosensitivity in Pten+/–Eμ-Myc and 
Eμ-Myc/eIF4E tumors in vivo. (A) Silvestrol sensitizes 
Pten+/–Eμ-Myc tumors to the effects of doxorubicin in 
vivo. Kaplan-Meier plot showing tumor-free survival of 
mice bearing Pten+/–Eμ-Myc tumors following treatment 
with doxorubicin (Dxr, solid black line; n = 10), rapamycin 
(Rap, dashed green line; n = 9), rapamycin and doxorubi-
cin (Rap + Dxr; solid blue line; n = 8), silvestrol (Sil, solid 
red line; n = 10), or silvestrol and doxorubicin (Sil + Dxr, 
dashed red line; n = 8). (B) Silvestrol does not alter drug 
response in Eμ-Myc/Bcl-2 tumors in vivo. Kaplan-Meier 
plot showing tumor-free survival of mice bearing Eμ-
Myc/Bcl-2 tumors following treatment with Dxr (n = 9), Sil 
(n = 7), or Sil + Dxr (n = 8). (C) Silvestrol sensitizes Eμ-
Myc/eIF4E tumors to the effects of Dxr in vivo. Kaplan-
Meier plot showing tumor-free survival of mice bearing 
Eμ-Myc/eIF4E tumors following treatment with Rap + Dxr 
(n = 10), Dxr (n = 11), Sil (n = 10), or Sil + Dxr (n = 10). 
(D) Western blot analysis of Eμ-myc/eIF4E (lane 1) and 
Pten+/–Eμ-Myc lymphomas (lanes 2–6). Lysates prepared 
from Eμ-myc/eIF4E or Pten+/–Eμ-Myc lymphomas from 
untreated (lanes 1, 2, and 4) and rapamycin- (lane 3), 
doxorubicin- (lane 5), and silvestrol-treated (lane 6) 
animals were subjected to immunoblotting for analysis 
of phosphorylated and total ribosomal S6 protein (p-S6 
and S6) and Akt (p-Akt and Akt). (E) Silvestrol inhibits 
translation in Pten+/–Eμ-Myc tumors in vivo. Mice bearing 
Pten+/–Eμ-Myc tumors were injected with MeOH or silves-
trol (0.2 mg/kg). Cytoplasmic extracts were prepared from 
tumors 4 hours later and resolved on 10%–50% sucrose 
gradients by centrifugation in an SW40 rotor at 150,000 g 
for 2 hours. Fractions were collected and monitored using 
an ISCO UA-6 UV detector. Plotted are results of 1 rep-
resentative experiment of 3 that showed similar results. 
The positions in the gradients of 40S and 80S ribosomes 
are labeled, and the polysome/monosome (P/M) ratios 
are indicated.
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Silvestrol synergizes with doxorubicin to 
induce apoptosis in Pten+/–Eμ-Myc lymphoma 
cells in vivo. (A) Representative micrographs 
(original magnification, ×200) of Pten+/–Eμ-
Myc lymphoma sections stained with H&E and 
TUNEL. C57BL/6 mice bearing well-palpable 
tumors were injected with vehicle, silvestrol, or 
rapamycin. Twenty-four hours later, the mice 
were injected again with silvestrol or rapamy-
cin alone or in combination with doxorubicin. 
Three and 6 hours after treatment, tumors 
were extracted and stained. (B) Amount of 
tumor cells positive for TUNEL staining per 
1,000 cells following the treatments described 
in A. The cell count was obtained from 4 dif-
ferent fields taken from 2 different sections. 
Results are expressed as mean ± SD. In vehi-
cle-treated cells, there were 36 ± 1 TUNEL-
positive cells/1,000 cells. (C) Western blot 
analysis of Pten+/–Eμ-Myc lymphomas treated 
as described in A. Tumor cells were extracted 
and lysed and the amount of cleaved 
poly(ADP-ribose) polymerase (c-PARP) and 
tubulin determined by Western blotting.
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In vivo metabolic labeling studies. Briefly, 6 × 104 HeLa cells were seeded 
into 24-well plates 1 day prior to the experiment. Cells were incubated in 
the presence of compound or vehicle for the indicated periods of time. 
[35S]methionine  (150–225 μCi/ml) and  [3H]uridine  (24 μCi/ml) were 
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